Trial Profile
A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- 22 Jul 2023 Planned End Date changed from 31 Dec 2022 to 20 Jul 2024.
- 01 Jun 2022 Planned End Date changed from 31 May 2022 to 31 Dec 2022.
- 01 Jun 2022 Planned primary completion date changed from 31 May 2022 to 31 Dec 2022.